Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Vertex Pharmaceuticals IncorporatedVRTX · NASDAQ

Regular Market · Oct 30, 02:57 PM

$559.56+$19.56 +3.62%

High: —
Low: —
Volume: —

Loading chart…

Ask Alva about VRTX

Vertex Pharmaceuticals Incorporated

VRTX · Biotechnology

559.56 USD

+19.56 (+3.62%)

Regular Market

High
Low
Volume
Open
Prev Close
Turnover
Trailing P/E
Market Cap
Turnover Ratio
Free Float
Post-Market
VWAP
Range (%)
Volume Ratio
52-Wk High
52-Wk Low
Forward P/E
Beta

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Regular Market

559.56 USD

+19.56 (+3.62%)

High
Low
Volume
Open
Prev Close
Turnover
Trailing P/E
Market Cap
Turnover Ratio
Free Float
Post-Market
VWAP
Range (%)
Volume Ratio
52-Wk High
52-Wk Low
Forward P/E
Beta

Unusual Price Movement

VRTX's unusually heavy volume accompanied the same healthcare-led rise, with recent kidney-drug safety scrutiny still in the background.

No new catalyst: trading volume turned unusually heavy while VRTX continued the healthcare-led move already under way. XLV and Sanofi rose as VRTX gained despite the broader market selloff; recent scrutiny of infection risk for Vertex's kidney-disease drug remained a secondary stock-specific factor.

statnews.com

Unusual Price Movement

VRTX's unusually heavy volume accompanied the same healthcare-led rise, with recent kidney-drug safety scrutiny still in the background.

Sources:

Vertex kidney disease drug scrutinized for infection risk

Ask Alva anything. @ for context, / for skills

Ask Alva about VRTX

VRTX's unusually heavy volume accompanied the same healthcare-led rise, with recent kidney-drug safety scrutiny still in the background. ⓘ

VRTX's unusually heavy volume accompanied the same healthcare-led rise, with recent kidney-drug safety scrutiny still in the background. ⓘ

VRTX's unusually heavy volume accompanied the same healthcare-led rise, with recent kidney-drug safety scrutiny still in the background.

VRTX's unusually heavy volume accompanied the same healthcare-led rise, with recent kidney-drug safety scrutiny still in the background.